ArticleBritish journal of cancer2013
An inherited NBN mutation is associated with poor prognosis prostate cancer.
Article in British journal of cancer, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 52 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
52 citing papers in PubMed, 2 syntheses or guidelines pooled it, 98 citations in OpenAlex.
- Germline mutations in prostate cancer: a systematic review of the evidence for personalized medicine.Prostate cancer and prostatic diseases · 2023Pooled it
- BRCA1 and BRCA2 pathogenic variants and prostate cancer risk: systematic review and meta-analysis.British journal of cancer · 2022Pooled it
- Association analysis of germline variants in GEN1 with a susceptibility to prostate cancer in Polish men.Hereditary cancer in clinical practice · 2026Article
- Germline Testing for Prostate Cancer Patients: Evidence-Based Evaluation of Genes Recommended by NCCN Guidelines.The Prostate · 2025Article
- Identification of Genes with Rare Loss of Function Variants Associated with Aggressive Prostate Cancer and Survival.European urology oncology · 2024Article
- Prostate cancer genetic background. The introduction of genetic testing in the determination of high-risk prostate cancer cases and selection of targeted chemotherapy in advanced prostate cancer patients.Central European journal of urology · 2024Review
- Germline DNA Damage Response Gene Mutations in Localized Prostate Cancer.Medicina (Kaunas, Lithuania) · 2023Article
- Impact of germline DNA repair gene variants on prognosis and treatment of men with advanced prostate cancer.Scientific reports · 2023Article
- Molecular basis and therapeutic targets in prostate cancer: A comprehensive review.Biomolecules & biomedicine · 2023Review
- Article
- Frequency of Germline and SomaticCancers · 2023Review
- Importance of Germline and Somatic Alterations in HumanInternational journal of molecular sciences · 2023Review
- NBN Pathogenic Germline Variants are Associated with Pan-Cancer Susceptibility and In Vitro DNA Damage Response Defects.Clinical cancer research : an official journal of the American Association for Cancer Research · 2023Article
- Mutational spectrum of DNA damage and mismatch repair genes in prostate cancer.Frontiers in genetics · 2023Review
- Comprehensive Clinical and Genetic Analysis ofGenes · 2022Article
- Ex vivo γH2AX assay for tumor radiosensitivity in primary prostate cancer patients and correlation with clinical parameters.Radiation oncology (London, England) · 2022Article
- Germline genetics of prostate cancer.The Prostate · 2022Review
- An appraisal of genetic testing for prostate cancer susceptibility.NPJ precision oncology · 2022Review
- Review
- Uterine carcinosarcoma associated with a germline nibrin (Gynecologic oncology reports · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
40 authors at 11 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundTo establish the contribution of eight founder alleles in three DNA damage repair genes (BRCA1, CHEK2 and NBS1) to prostate cancer in Poland, and to measure the impact of these variants on survival among patients.
methodsThree thousand seven hundred fifty men with prostate cancer and 3956 cancer-free controls were genotyped for three founder alleles in BRCA1 (5382insC, 4153delA, C61G), four alleles in CHEK2 (1100delC, IVS2+1G>A, del5395, I157T), and one allele in NBS1 (657del5).
resultsThe NBS1 mutation was detected in 53 of 3750 unselected cases compared with 23 of 3956 (0.6%) controls (odds ratio (OR)=2.5; P=0.0003). A CHEK2 mutation was seen in 383 (10.2%) unselected cases and in 228 (5.8%) controls (OR=1.9; P<0.0001). Mutation of BRCA1 (three mutations combined) was not associated with the risk of prostate cancer (OR=0.9; P=0.8). In a subgroup analysis, the 4153delA mutation was associated with early-onset (age ≤ 60 years) prostate cancer (OR=20.3, P=0.004). The mean follow-up was 54 months. Mortality was significantly worse for carriers of a NBS1 mutation than for non-carriers (HR=1.85; P=0.008). The 5-year survival for men with an NBS1 mutation was 49%, compared with 72% for mutation-negative cases.
conclusionA mutation in NBS1 predisposes to aggressive prostate cancer. These data are relevant to the prospect of adapting personalised medicine to prostate cancer prevention and treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.